Kangstem Biotech Statistics

Total Valuation

Kangstem Biotech has a market cap or net worth of KRW 118.83 billion. The enterprise value is 96.24 billion.

Market Cap	118.83B
Enterprise Value	96.24B

Important Dates

The last earnings date was Tuesday, November 12, 2024.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Kangstem Biotech has 56.05 million shares outstanding. The number of shares has increased by 30.75% in one year.

Current Share Class	n/a
Shares Outstanding	56.05M
Shares Change (YoY)	+30.75%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	5.94%
Owned by Institutions (%)	0.19%
Float	44.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.92
PB Ratio	2.31
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.86
EV / Sales	7.25
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.59

Financial Position

The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.15.

Current Ratio	3.09
Quick Ratio	2.44
Debt / Equity	0.15
Debt / EBITDA	n/a
Debt / FCF	-0.44
Interest Coverage	-23.70

Financial Efficiency

Return on equity (ROE) is -25.70% and return on invested capital (ROIC) is -23.01%.

Return on Equity (ROE)	-25.70%
Return on Assets (ROA)	-18.75%
Return on Capital (ROIC)	-23.01%
Revenue Per Employee	136.88M
Profits Per Employee	-100.67M
Employee Count	97
Asset Turnover	0.19
Inventory Turnover	13.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.61% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+53.61%
50-Day Moving Average	1,869.00
200-Day Moving Average	2,140.81
Relative Strength Index (RSI)	54.58
Average Volume (20 Days)	1,158,500

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kangstem Biotech had revenue of KRW 13.28 billion and -9.76 billion in losses. Loss per share was -196.85.

Revenue	13.28B
Gross Profit	1.89B
Operating Income	-20.79B
Pretax Income	-11.80B
Net Income	-9.76B
EBITDA	-17.05B
EBIT	-20.79B
Loss Per Share	-196.85

Full Income Statement

Balance Sheet

The company has 30.26 billion in cash and 7.66 billion in debt, giving a net cash position of 22.59 billion or 403.07 per share.

Cash & Cash Equivalents	30.26B
Total Debt	7.66B
Net Cash	22.59B
Net Cash Per Share	403.07
Equity (Book Value)	51.49B
Book Value Per Share	918.56
Working Capital	26.91B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -15.78 billion and capital expenditures -1.45 billion, giving a free cash flow of -17.23 billion.

Operating Cash Flow	-15.78B
Capital Expenditures	-1.45B
Free Cash Flow	-17.23B
FCF Per Share	-307.36

Full Cash Flow Statement

Margins

Gross margin is 14.22%, with operating and profit margins of -156.55% and -73.54%.

Gross Margin	14.22%
Operating Margin	-156.55%
Pretax Margin	-88.90%
Profit Margin	-73.54%
EBITDA Margin	-128.41%
EBIT Margin	-156.55%
FCF Margin	-129.76%

Dividends & Yields

Kangstem Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.75%
Shareholder Yield	-30.75%
Earnings Yield	-9.29%
FCF Yield	-14.50%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kangstem Biotech has an Altman Z-Score of 0.18. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.18
Piotroski F-Score	n/a